Will Arrowhead Pharmaceuticals Be a Biotech Winner?
With seven gene silencing candidates currently in clinical trials, Arrowhead Pharmaceuticals (NASDAQ: ARWR) is making rapid progress in developing solutions to some of the rarest and most difficult-to-treat diseases around the world today.
The company's efforts have attracted attention across the industry. Although the studies are in their early phases, the efficacy data from Arrowhead's clinical candidates indicate it may have developed several breakthrough therapies. Let's take a look at why the company is a solid buy that will keep biotech investors satisfied for years to come.
Image source: Getty Images.
Source Fool.com
